Company Update: Bristol-Myers Squibb Company (NYSE:BMY) – Second-Generation Investigational HIV-1 Maturation Inhibitor Demonstrates Positive New Phase IIa Results, Supporting Continued Development

[Business Wire] – Bristol-Myers Squibb Company today announced additional Phase IIa proof-of-concept data for BMS-955176, a novel investigational agent designed to prevent the maturation of HIV-1. Read more on this. Bristol-Myers Squibb . . . → Read More: Company Update: Bristol-Myers Squibb Company (NYSE:BMY) – Second-Generation Investigational HIV-1 Maturation Inhibitor Demonstrates Positive New Phase IIa Results, Supporting Continued Development Similar Articles: Company Update: Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb Announces the Expiration of its Cash Tender Offer Market Update (NYSE:BMY): Bristol-Myers Squibb Receives Amended U.S. FDA Breakthrough Therapy Designation for Investigational Daclatasvir-based Hepatitis C Regimen Stock Update (NYSE:BMY): Bristol-Myers Squibb to Present at Bank of America Merrill Lynch 2015 Health Care Conference